AZ, MSD’s Koselugo bags US approval
The drug is the first in the world to be approved to treat this rare and debilitating genetic condition
Read More
Tag: Selumetinib
AZ’s Selumetinib granted US Breakthrough Therapy Designation
The BTD is for the treatment of paediatric patients aged three years and older with neurofibromatosis type 1 (NF1).
Read More
Trial to test cancer combo in both adults and children
UK researchers have launched an early stage trial designed to help assess whether AstraZeneca and MSD’s selumetinib could be effective in combination with dexamethasone as a treatment for leukaemia.
Read More
Arthritis drug shows potential in skin cancer
The effectiveness of melanoma treatment could be boosted if combined with a well-known drug for rheumatoid arthritis (RA), indicates early UK research.
Read More
AZ, Merck link to develop and commercialise cancer drugs
In a bumper news day for AstraZeneca, the firm announced a deal with Merck & Co to co-develop and co-commercialise Lynparza and selumetinib for multiple cancer types, second-quarter results in line with expectations, initial trial data showing the failure of Imfinzi to boost PFS in lung cancer patients, and other trial data in lung cancer showing the success of Tagrisso in improving PFS.
Read More
Another late-stage trial failure for AZ’ selumetinib
AstraZeneca’s MEK 1/2 inhibitor selumetinib has suffered another blow after failing to hit targets in a late-stage trial assessing its safety and effectiveness alongside docetaxel in patients with a certain form of lung cancer.
Read More
- CERo reports encouraging early data from phase 1 trial of CER‑1236
- ENA Respiratory begins dosing in phase 2 study of INNA‑051 nasal spray
- Argo Biopharma doses first patient in phase 2b trial of BW‑20829
- Akari files new patent and advances second ADC targeting CEACAM5
- BioMed X launches kidney disease project in partnership with the government of Barbados
